Group
|
GSH (μM/g tissue)
|
GR (nM/min/mg protein)
|
GST (nM/min/mg protein)
|
γ-GT (nM/min/mg Protein)
|
GPx (nM/min/mg Protein)
|
---|
Control
|
19.61 ± 0.28 b
|
163.6 ± 0.65 b
|
142.6 ± 0.57 b
|
336.2 ± 0.56 b
|
139.5 ± 1.16 b
|
CP
|
10.08 ± 0.28 a
|
103.9 ± 0.65 a
|
101.4 ± 0.84 a
|
143.6 ± 1.44 a
|
90.53 ± 1.71 a
|
AHE alone
|
20.11 ± 0.16 b
|
164.2 ± 0.68 b
|
142.7 ± 0.89 b
|
336.3 ± 1.0 b
|
139.8 ± 0.36 b
|
CP + AHE
|
12.83 ± 0.21a,b d
|
122.8 ± 0.65a,b,d
|
122.1 ± 0.87a,b,d
|
215.3 ± 1.85a,b,d
|
108.6 ± 1.25 a,b
|
AHE + CP
|
18.38 ± 0.29a*,b, c
|
145.5 ± 0.58a,b,c
|
135.3 ± 0.77a,b, c
|
310.4 ± 0.6 a,b,c
|
128.6 ± 1.74 a,b
|
CP + Sily
|
18.34 ± 0.11a*,b
|
148.7 ± 1.09 a, b
|
130.0 ± 0.92 a, b
|
309.5 ± 0.69 a, b
|
131.8 ± 1.28 a,b
|
- Values expressed as mean ± SEM
-
a Significance at p < 0.0001 Vs. control group
-
b Significance at p < 0.0001 Vs. Cisplatin (CP) group
-
c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group
-
d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group
-
* Significant difference at p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests)